US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Monkeypox Concept

1,668.66

+3.050.18%

Number of Gainers:3

Number of Losers:7

Number of Flat:1

PE:- -

High:1,688.91

Open:1,665.61

Low:1,651.36

Close:1,665.61

Volume:25.58M

Turnover:1.12B

Market Cap:185.83B

Float Cap:185.27B

Loading ...

Geovax Labs Inc trading halted, news pending

Assessing SIGA Technologies (SIGA) Valuation As Biodefense Strength Draws Renewed Investor Attention

Simply Wall St.

Does Quest’s Deeper Corewell Tie-Up Reshape Its Hospital Lab Strategy And Investment Case (DGX)?

Simply Wall St.

Clinical Labs Hope to Head Off Looming Medicare Cuts -- Barrons.com

Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances

Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright

Gilead price target raised to $154 from $144 at BofA

BRIEF-Emergent Bio- Receives $21.5 Mln Order From U.S. Department Of War To Supply Biothrax In 2026

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

Emergent BioSolutions Inc - Receives $21.5 Mln Order From U.S. Department of War to Supply Biothrax in 2026

THOMSON REUTERS

Emergent BioSolutions Receives $21.5 Million Order to Supply Anthrax Vaccine to U.S. Department of War

Is Quest Diagnostics (DGX) Pricing Look Attractive After Recent DCF And P/E Checks

Simply Wall St.

Gilead voluntarily recalls one lot of Veklury for Injection 100 mg/vial

Viatris names Lara Ramsburg as Chief People and Corporate Affairs Officer

Press Release: Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Emergent BioSolutions Partners with PANTHER to Support Africa CDC-Led Mpox Study

Emergent BioSolutions and Panther Announce Agreement to Support the Continuation of the Africa Cdc-Led Mpox Study in Africa

THOMSON REUTERS

Emergent BioSolutions Inc - Africa Cdc and Panther to Extend Study to Uganda

THOMSON REUTERS

Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers

Gilead : RBC Cuts Target Price to $100 From $105

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1668.6576,"timestamp":1767992399999,"preClose":1665.6113,"halted":0,"volume":25583758,"delay":0,"changeRate":0.001829,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":3.046265,"latestTime":"01-09 16:00:00 EST","open":1665.6085,"high":1688.912,"low":1651.363,"amount":1116233966.117947,"amplitude":0.022544,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.218152,"peRate":35.924742,"turnoverRate":0.009445,"increases":3,"decrements":7,"flats":0,"marketCap":185825537999.75,"floatMarketCap":185271458933},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1688.912,"amplitude":0.022544,"preClose":1665.6113,"low":1651.363,"pbRate":"4.218152","latestPrice":1668.6576,"volume":25583758,"delay":0,"open":1665.6085,"prevYearClose":1682.3505,"prevWeekClose":1670.2272,"prevMonthClose":1682.3505,"prevQuarterClose":1682.3505,"fiveDayClose":1670.2272,"twentyDayClose":1664.4589,"sixtyDayClose":1619.8052,"secType":"PLATE","market":"US","turnoverRate":0.009445,"peRate":35.924742,"marketCap":185825537999.75,"floatMarketCap":185271458933,"timestamp":1767992399999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":3,"down":7,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602300456","title":"Geovax Labs Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602300456?lang=en_us&edition=fundamental","pubTime":"2026-01-10 08:50","pubTimestamp":1768006228,"startTime":"0","endTime":"0","summary":"19:50 EST Geovax Labs (GOVX) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/geovax-labs-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/geovax-labs-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GOVX","BK4583"],"gpt_icon":0},{"id":"2602071593","title":"Assessing SIGA Technologies (SIGA) Valuation As Biodefense Strength Draws Renewed Investor Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2602071593","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602071593?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:26","pubTimestamp":1767997616,"startTime":"0","endTime":"0","summary":"Why SIGA is back on investors’ radar\nSIGA Technologies (SIGA) is drawing fresh attention after recent coverage highlighted its TPOXX smallpox antiviral, consistent profitability, and solid balance sheet, even as major new contract or regulatory announcements remain quiet.\nSee our latest analysis for SIGA Technologies.\nAt a share price of US$6.77, SIGA has seen a 10.8% 7 day share price return and an 8.3% 30 day share price return, while its 1 year total shareholder return of 19.1% points to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/assessing-siga-technologies-siga-valuation-as-biodefense-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/assessing-siga-technologies-siga-valuation-as-biodefense-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4583","BK4007","DCF","SIGA"],"gpt_icon":0},{"id":"2602307130","title":"Does Quest’s Deeper Corewell Tie-Up Reshape Its Hospital Lab Strategy And Investment Case (DGX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602307130","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602307130?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:25","pubTimestamp":1767997543,"startTime":"0","endTime":"0","summary":"Corewell Health and Quest Diagnostics recently completed their Diagnostic Lab of Michigan joint venture, giving Quest 51% ownership and extending its Collaborative Lab Solutions across 21 Corewell hospitals, with a new facility planned for early 2027.\nThis majority-owned partnership meaningfully deepens Quest’s hospital footprint in Michigan, potentially reinforcing its role as an outsourced lab partner for large health systems.\nWe’ll now examine how this expanded Corewell partnership, and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/does-quests-deeper-corewell-tie-up-reshape-its-hospital-lab","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/does-quests-deeper-corewell-tie-up-reshape-its-hospital-lab","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0823417653.USD","LU1854104046.USD","BK4588","DGX","LU0823417737.USD","BK4196","LU1854103824.USD","LU2506951875.HKD","LU2506952097.USD","LU2506952170.USD","BK4583","LU0950375773.USD","BK4567","LU2506951958.HKD","BK4585"],"gpt_icon":0},{"id":"2602830682","title":"Clinical Labs Hope to Head Off Looming Medicare Cuts -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2602830682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602830682?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:24","pubTimestamp":1767986640,"startTime":"0","endTime":"0","summary":"U.S. House representatives heard the clinical lab industry plead yesterday for a reprieve from looming cuts as large as 15% in what Medicare pays Labcorp Holdings, Quest Diagnostics and cancer-testing specialists like Guardant Health, Exact Sciences, and Natera.Starting February, a current law will require labs to tell Medicare the rates that private insurers paid for tests back in 2019. Medicare will then cut its own test payments to those levels in 2027.That will hurt the development of technologies like the genomic tests now used for diagnosing cancer patients and sick infants, said American Clinical Laboratory Association President Susan Van Meter, at a Thursday hearing on Medicare reimbursement rates.The February deadline exists because of a law passed 10 years ago that made clinical labs the only healthcare industry whose Medicare rates would match those paid by private insurers. Commercial rates were first surveyed in 2016 and Medicare cut its test payments by up to 10% in each ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854103824.USD","HOPE","LH","LU2506951875.HKD","LU0823417737.USD","BK4567","BK4550","LU0742534661.SGD","GH","LU0823417653.USD","BK4588","LU2324357040.USD","LU1861558580.USD","LU2237438978.USD","LU0251142724.SGD","LU1861559042.SGD","LU1854104046.USD","LU0266013472.USD","BK4211","DGX","BK4551","EXAS","BK4583","BK4548","LU0006061336.USD","LU2506952097.USD","BK4139","BK4196","BK4535","LU2506951958.HKD","LU0251131958.USD","BK4585","LU2506952170.USD","LU0950375773.USD","LU1059921491.USD","LU0048573561.USD"],"gpt_icon":0},{"id":"2602303943","title":"Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2602303943","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602303943?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:56","pubTimestamp":1767981413,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can acc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9ZV19s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"2602035113","title":"Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2602035113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602035113?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:26","pubTimestamp":1767979572,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Virax Biolabs (VRAX) to $1 from $3 and keeps a Buy rating on the shares. Virax Biolabs outlined ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/virax-biolabs-price-target-lowered-to-1-from-3-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/virax-biolabs-price-target-lowered-to-1-from-3-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4175","BK4583","VRAX"],"gpt_icon":0},{"id":"2602374415","title":"Gilead price target raised to $154 from $144 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602374415?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:25","pubTimestamp":1767968732,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Gilead (GILD) to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-154-from-144-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-154-from-144-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3T34201.USD","GILD","BK4532","IE0002270589.USD","LU0289739699.SGD","LU1674673428.USD","SG9999015986.USD","LU1585245621.USD","LU2324357040.USD","BK4585","IE00B19Z3581.USD","LU1066053197.SGD","LU1571399168.USD","SG9999015978.USD","BK4566","BK4588","LU0234570918.USD","LU0889565916.HKD","LU0114720955.EUR","BK4583","SG9999015945.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","LU0823416689.USD","LU0882574055.USD","LU0058720904.USD","BK4139","BK4550","LU1066051498.USD","LU2089984988.USD","BK4578","LU0320765992.SGD","IE00BSNM7G36.USD","LU1839511570.USD","LU2087621335.USD","BK4568","LU0109394709.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2602831317","title":"BRIEF-Emergent Bio- Receives $21.5 Mln Order From U.S. Department Of War To Supply Biothrax In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602831317","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602831317?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:41","pubTimestamp":1767908463,"startTime":"0","endTime":"0","summary":"BRIEF-Emergent Bio- Receives $21.5 Mln Order From U.S. Department Of War To Supply Biothrax In 2026Jan 8 (Reuters) - Emergent BioSolutions Inc EBS.N:EMERGENT BIOSOLUTIONS INC - RECEIVES $21.5 MILLION ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"2602575313","title":"Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2602575313","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602575313?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:36","pubTimestamp":1767908160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  shed 2.96% to $120.67 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.01% to 6,921.46 and the Dow Jones Industrial Average  rising 0.55% to 49,266.11.The stock's fall snapped a two-day winning streak.Gilead Sciences Inc. closed 6.24% below its 52-week high of $128.70, which the company reached on November 20th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  fell 0.84% to $205.75, Pfizer Inc.  rose 0.04% to $25.29, and Abbott Laboratories  fell 0.68% to $126.18.Trading volume  remained 187,470 below its 50-day average volume of 6.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled January 8, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU1929549753.HKD","LU1721429402.USD","IE00B42XCP33.USD","LU1989763427.SGD","BK4599","LU1066053197.SGD","IE00B2B36J28.USD","LU1196500208.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU2324357040.USD","LU0432979614.USD","LU0882574055.USD","IE00B3T34201.USD","BK4585","LU2471134879.HKD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","LU2087621335.USD","LU1989763690.USD","IE00BZ1G4Q59.USD","SG9999002232.USD","IE0002141913.USD","LU1691799644.USD","LU0795875169.SGD","BK4007","LU2237957811.SGD","LU2471134952.CNY","IE00BVYPNV92.GBP","LU1883839398.USD","LU1267930813.SGD","SG9999013999.USD","SG9999002224.SGD","LU2592432038.USD","IE00BLSP4239.USD","LU1032466523.USD","LU1032955483.USD","LU2112291526.USD","BK4581","LU1244550577.SGD","LU2129689605.HKD","IE00B1BXHZ80.USD","LU0683600562.USD","IE00B4R5TH58.HKD","LU0889566641.SGD","LU1244550221.USD","LU0889565916.HKD","SG9999001176.USD","LU2430703178.SGD","LU0345769631.USD","LU1674673428.USD","BK4534","LU0098860793.USD","IE00BDGV0183.EUR","LU0456855351.SGD","LU0203345920.USD","BK4504","BK4559","BK4588","IE00BVYPNW00.USD","LU0114720955.EUR","LU0203347892.USD","LU1066051225.USD","LU1244550494.USD","IE00B3PB1722.GBP","LU2129689431.USD","LU2430703095.HKD","LU2505996681.GBP","SG9999015986.USD","LU0234570918.USD","LU1023059063.AUD","LU0306806265.USD","BK4082","SG9999001176.SGD","SG9999001440.SGD","LU2468319806.SGD","LU0345769128.USD","IE00B19Z3B42.SGD","LU0070217475.USD","LU0225284248.USD","LU0787776722.HKD","BK4568","LU1074936037.SGD","LU1732799900.SGD","LU2471134523.USD","LU1430594728.SGD","LU1061106388.HKD","LU1221951046.USD","LU1914381329.SGD","LU0170899867.USD","LU1057294990.SGD","LU0345770993.USD","LU1894683348.USD","SG9999003800.SGD","LU2129689514.USD","IE00BBT3K403.USD","BK4583","SGXZ23171101.USD","LU0985481810.HKD","LU1721429741.USD","GILD","LU0321505868.SGD","LU0912757837.SGD","LU0640476718.USD","LU1162221912.USD","SG9999004303.SGD","IE00BLSP4452.SGD","LU0225771236.USD","LU1718418525.SGD","LU2347655156.SGD","IE00BN8TJ469.HKD","IE0034235303.USD","LU0985320562.USD","LU0320765646.SGD","LU1280957306.USD","LU2505996509.AUD","LU0306807586.USD","SGXZ57979304.SGD","LU0058720904.USD","BK4566","LU0289739699.SGD","LU1935042991.SGD","LU1732800096.USD","LU2211815571.USD","SG9999015945.SGD","LU0466842654.USD","LU1778281490.HKD","LU0345770308.USD","LU0689626769.HKD","LU1066051498.USD","LU2430703251.USD","LU1894683264.USD","SG9999015978.USD","LU2133065610.SGD","IE00B19Z3581.USD","LU0266013472.USD","LU1496350502.SGD","LU1585245621.USD","BK4139","LU0320765992.SGD","IE000M9KFDE8.USD","LU1066051811.HKD","LU0868494617.USD","LU0823416689.USD","IE00B7SZLL34.SGD","BK4533","LU1221951129.SGD","BK4532","BK4592","LU2750360997.AUD","LU1839511570.USD","IE00BGHQF631.EUR","SG9999015952.SGD","BK4550","BK4578","LU1059921491.USD","LU0792757196.USD","LU1571399168.USD","LU0109394709.USD","LU2471134796.USD","LU2089984988.USD","LU0124676726.USD","IE00BJJMRZ35.SGD","LU2237957902.USD","LU2750360641.GBP","SG9999011175.SGD","IE00BJT1NW94.SGD","LU1261432733.SGD","LU1674673691.USD","LU2602419157.SGD","IE00BFXG1179.USD","LU0122379950.USD","LU1506573853.SGD","SGXZ41872573.SGD","LU0234572021.USD","IE0002270589.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2602313841","title":"Emergent BioSolutions Inc - Receives $21.5 Mln Order From U.S. Department of War to Supply Biothrax in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313841?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:31","pubTimestamp":1767907899,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2602313861","title":"Emergent BioSolutions Receives $21.5 Million Order to Supply Anthrax Vaccine to U.S. Department of War","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313861","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313861?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:30","pubTimestamp":1767907832,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL76wfGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4583","EBS","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","BK4112","LU0314104364.USD","SG9999014039.USD","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2602397582","title":"Is Quest Diagnostics (DGX) Pricing Look Attractive After Recent DCF And P/E Checks","url":"https://stock-news.laohu8.com/highlight/detail?id=2602397582","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602397582?lang=en_us&edition=fundamental","pubTime":"2026-01-09 02:42","pubTimestamp":1767897750,"startTime":"0","endTime":"0","summary":"If you are wondering whether Quest Diagnostics at around US$178 per share represents good value today, looking closely at what you are paying for each dollar of its business can be a useful next step.\nThe stock has recently shown mixed returns, with a 2.7% gain over the last 7 days, a 2.0% decline over the last 30 days, and returns of 2.5% year to date, 17.8% over 1 year, 23.8% over 3 years, and 56.6% over 5 years.\nRecent coverage of Quest Diagnostics has focused on its role in diagnostic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/is-quest-diagnostics-dgx-pricing-look-attractive-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/is-quest-diagnostics-dgx-pricing-look-attractive-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU1854103824.USD","BK4196","LU2506951875.HKD","LU0823417737.USD","DGX","LU1854104046.USD","BK4567","LU2506951958.HKD","LU0823417653.USD","BK4583","LU2506952097.USD","LU0950375773.USD","LU2506952170.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2602396050","title":"Gilead voluntarily recalls one lot of Veklury for Injection 100 mg/vial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602396050","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602396050?lang=en_us&edition=fundamental","pubTime":"2026-01-09 00:30","pubTimestamp":1767889817,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced it is issuing a voluntary recall of one lot of Veklury for Injection 100 mg/vial, to the consumer level. Gilead re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-voluntarily-recalls-one-lot-of-veklury-for-injection-100-mg-vial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-voluntarily-recalls-one-lot-of-veklury-for-injection-100-mg-vial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3T34201.USD","BK4583","BK4588","LU1571399168.USD","BK4532","LU1585245621.USD","IE00B19Z3581.USD","BK4566","LU2087621335.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU0320765992.SGD","LU1674673428.USD","LU2089984988.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU1778281490.HKD","LU0109394709.USD","GILD","IE0002270589.USD","LU0114720955.EUR","LU0889565916.HKD","LU1674673691.USD","SG9999015986.USD","SG9999015978.USD","BK4568","LU1839511570.USD","BK4585","IE00BKVL7J92.USD","SG9999015952.SGD","BK4550","LU2468319806.SGD","LU2324357040.USD","LU0234570918.USD","LU0823416689.USD","LU1066051498.USD","LU1430594728.SGD","SG9999015945.SGD","LU0058720904.USD","LU0289739699.SGD","BK4578","BK4139","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2601922360","title":"Viatris names Lara Ramsburg as Chief People and Corporate Affairs Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601922360","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601922360?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:18","pubTimestamp":1767881882,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) announced that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris’ ongoing transformati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viatris-names-lara-ramsburg-as-chief-people-and-corporate-affairs-officer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viatris-names-lara-ramsburg-as-chief-people-and-corporate-affairs-officer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","LU1839511570.USD","BK4585","LU2087621335.USD","BK4588","VTRS","BK4007"],"gpt_icon":0},{"id":"2601336088","title":"Press Release: Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336088","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336088?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:05","pubTimestamp":1767881100,"startTime":"0","endTime":"0","summary":"PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc.  announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional teams that drive results. She is also a respected strategic communicator, using purpose-driven messaging to help organizations achieve their objectives and build meaningful relationships with both internal and external stakeholders.Viatris Inc.  is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare need","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4583","VTRS","BK4588","BK4007","BK4585","LU2087621335.USD"],"gpt_icon":0},{"id":"2601835364","title":"Emergent BioSolutions Partners with PANTHER to Support Africa CDC-Led Mpox Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835364","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601835364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877256,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc. has announced a collaboration agreement with PANTHER to provide additional financial support for the continuation of the Africa CDC-led 'MpOx Study in Africa' . This double-blind, platform-adaptive clinical trial, launched in 2024 and initially funded by the European Union and Africa CDC, aims to evaluate potential treatment options for mpox, a virus currently lacking a dedicated antiviral therapy. The study, which has already enrolled patients across multiple African countries, will expand to new sites including Uganda. The partnership underscores Emergent’s commitment to advancing research and preparedness for global health threats in collaboration with international partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4Q7y66:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4583","IE00B64PRP62.GBP","NDAQ","BK4112","SG9999014005.SGD","EBS","LU2210149790.SGD"],"gpt_icon":0},{"id":"2601636438","title":"Emergent BioSolutions and Panther Announce Agreement to Support the Continuation of the Africa Cdc-Led Mpox Study in Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601636438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601636438?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA6YHMXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2601364810","title":"Emergent BioSolutions Inc - Africa Cdc and Panther to Extend Study to Uganda","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364810?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA6YHMXH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2601369847","title":"Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369847","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369847?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:01","pubTimestamp":1767873660,"startTime":"0","endTime":"0","summary":"Solution delivers secure boot, power management and system control for complex computingCHANDLER, Ariz., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Microchip Technology(Nasdaq: MCHP) has announced the releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215230/0/en/Microchip-Releases-Custom-Firmware-For-NVIDIA-DGX-Spark-For-Its-MEC1723-Embedded-Controllers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096362180.USD","IE00BK4W5L77.USD","LU1804176565.USD","LU0353189680.USD","LU1861215975.USD","NVDS.UK","LU0868494617.USD","LU2505996509.AUD","LU0642271901.SGD","LU1720051108.HKD","LU0310799852.SGD","BK4608","LU0823417653.USD","IE00BHPRN162.USD","LU0187121727.USD","LU1066051811.HKD","LU2265009873.SGD","LU0127658192.USD","LU0203202063.USD","LU1821325948.USD","LU0476273544.USD","LU1951200564.SGD","LU0964807845.USD","BK4583","HK0000306701.USD","IE00B19Z8W00.USD","IE00BD6J9T35.USD","LU0823414478.USD","IE0003U64NQ7.SGD","LU2168564065.EUR","LU2456880835.USD","LU1935042215.USD","LU0823421333.USD","LU2322448791.USD","LU0823434740.USD","LU0345769128.USD","LU2462157665.USD","LU1854104046.USD","LU0106261372.USD","IE00BJTD4V19.USD","LU2592432038.USD","SG9999014898.SGD","LU2756315664.SGD","LU1861127337.USD","LU1989764748.USD","IE00B3M56506.USD","NVDD","LU2087625088.SGD","SG9999001424.SGD","IE00BJJMRY28.SGD","IE000ITXATA3.USD","IE00BN29S564.USD","LU2023250504.SGD","LU2417539215.USD","LU0061474960.USD","LU2506952097.USD","LU2108987350.USD","LU2168563687.JPY","LU1242518931.SGD","2NVD.UK","LU0823417737.USD","NVD","LU0276348264.USD","LU1280957306.USD","LU2023250330.USD","LU0289960550.SGD","IE00BFSS8Q28.SGD","IE00BZ1G4Q59.USD","NVD2.UK","LU2272731600.USD","LU2125909593.SGD","SG9999017495.SGD","LU0345769631.USD","LU1868837136.USD","LU2089284900.SGD","SGXZ99366536.SGD","LU2746668461.USD","LU0788109477.HKD","LU2065170008.USD","LU2357305700.SGD","LU1366333091.USD","LU2211815571.USD","LU0080751232.USD","BK4614","LU2543165471.USD","LU1852331112.SGD","LU1712237335.SGD","LU0029864427.USD","BK4554","LU0820562030.AUD","LU2286300806.USD","SGXZ31699556.SGD","LU2471134952.CNY","LU1914381329.SGD","IE0034235188.USD","LU0354030438.USD","LU0494093205.USD","LU1116320901.HKD","BK4529","LU1815333072.USD","LU2250418816.HKD","LU2361045086.USD","LU2491049909.HKD","SG9999015986.USD","LU2420271590.USD","SG9999000418.SGD","LU2065171402.SGD","LU0157215616.USD","BK4581","LU2322448957.HKD","LU1989772840.SGD","BK4551","LU0965509101.SGD","LU2089985449.USD","LU0965509283.SGD","LU1917777945.USD","BK4527","LU1267930490.SGD","LU2097344357.USD","IE00BDCRKT87.USD","LU0444973449.USD","SG9999015978.USD","LU1699723380.USD","LU0965508806.USD","LU0965509010.AUD","LU2473716301.USD","LU1242518857.USD","IE00BKDWB100.SGD","LU2063271972.USD","LU0006306889.USD","LU0274383776.USD","IE0001KFT4U8.USD","LU1814569148.SGD","LU2471134523.USD","LU2242649171.HKD","LU2361044865.SGD","LU0109392836.USD","LU2249611893.SGD","LU2403377893.USD","LU1261432733.SGD","LU2430703251.USD","LU0528227936.USD","LU2506951958.HKD","LU1435385759.SGD","SG9999015952.SGD","LU2244417387.USD","LU0210533765.USD","LU2290526834.HKD","LU2461242641.AUD","LU0724617625.USD","IE00BYXW3230.USD","LU0170899867.USD","LU1854103824.USD","SG9999015358.SGD","IE00B4YYXB79.USD","LU2931357623.SGD","LU0417517546.SGD","BK4141","LU0861579265.USD","LU2242650005.HKD","LU0889565833.HKD","IE0009G5SDU7.USD","LU1934455277.USD","LU0251132253.USD","LU0719512351.SGD","LU2125154935.USD","IE00BJTD4N35.SGD","LU0354030511.USD","IE00B1XK9C88.USD","LU0289961442.SGD","SG9999014542.SGD","SG9999014567.USD","LU0310800379.SGD","LU0070217475.USD","SG9999002224.SGD","LU0640476718.USD","LU2087621335.USD","LU0225283273.USD","LU0215105999.USD","LU1974910355.USD","LU2433249047.HKD","LU2552382058.USD","IE00BQXX3C00.GBP","3NVD.UK","LU1571399168.USD","LU1429558221.USD","HK0000306685.HKD","LU1116320737.USD","SG9999018865.SGD","LU2191332357.HKD","LU0390134368.USD","LU0472753341.HKD","LU1778281490.HKD","SGXZ23171101.USD","LU1066053197.SGD","LU1316542783.SGD","LU0109391861.USD","BK4534","LU0107464264.USD","SG9999014575.USD","LU2213496289.HKD","LU0444971666.USD","LU1084165304.USD","LU2272731865.HKD","IE00BK4W5M84.HKD","LU0128525929.USD","IE00BMPRXN33.USD","LU1674673691.USD","LU2452424414.USD","LU0061474705.USD","LU0957808578.USD","LU1935042488.USD","LU0097036916.USD","LU0234572021.USD","LU1119994496.HKD","LU0057025933.USD","LU0308772762.SGD","LU0689472784.USD","BK4587","LU2360106780.USD","LU2750360997.AUD","IE00BMPRXQ63.HKD","LU1934455863.HKD","LU0238689110.USD","LU1674673428.USD","LU1323610961.USD","IE00B7KXQ091.USD","IE00B5949003.HKD","LU0061475181.USD","LU2491050071.SGD","IE00BJLML261.HKD","LU1496350171.SGD","LU1992135399.USD","IE000KEQY171.SGD","LU0985320562.USD","LU1923622291.USD","LU2360032135.SGD","SNVD.UK","BK4550","LU0256863811.USD","LU1366192091.USD","LU1548497426.USD","LU0158827781.USD","BK4503","IE00B19Z8X17.USD","IE0034235295.USD","LU2065171311.SGD","LU1244550577.SGD","LU0266013472.USD","IE00BWXC8680.SGD","IE00B19Z9505.USD","LU0256863902.USD","HK0000320223.HKD","IE00BKVL7J92.USD","LU1629891620.HKD","SG9999018857.SGD","LU0077335932.USD","LU1861220033.SGD","NVDU","LU0124676726.USD","LU0345768153.USD","LU1868836914.USD","IE00BZ199S13.USD","LU0868494708.USD","NVIW.SI","BK4549","LU2092937148.SGD","LU1232071149.USD","LU2487616109.SGD","LU2125909247.SGD","LU1803068979.SGD","LU2458330169.SGD","IE000W1ABFV2.USD","LU2092627202.USD","BK4196","LU2077746001.SGD","LU2491050154.USD","LU1720051017.SGD","LU0345770308.USD","LU0787776722.HKD","BK4598","IE00B3SWFQ91.USD","LU2505996681.GBP","LU0320765059.SGD","LU1935043536.SGD","LU0683600562.USD","IE0004086264.USD","LU2463028550.USD","LU1935042991.SGD","LU0234570918.USD","IE00BFSS7M15.SGD","SG9999014906.USD","IE0004445239.USD","NVDY","LU1691799644.USD","LU0689626769.HKD","LU0345770993.USD","LU0082616367.USD","LU1267930573.SGD","LU0823434583.USD","IE00BQXX3F31.USD","BK4532","LU0882574139.USD","BK4579","BK4588","LU1934455194.USD","LU0957791311.USD","IE00B775H168.HKD","LU0069063385.USD","LU2028103732.USD","LU0820561818.USD","IE0034235303.USD","SG9999014559.SGD","LU2360107168.USD","LU0079474960.USD","LU1989764664.SGD","LU0210528500.USD","LU0708994859.HKD","BK4543","IE000YTNTUN2.SGD","LU0289739343.SGD","LU1244550221.USD","LU1496350502.SGD","LU1066051225.USD","BK4567","LU2125909916.SGD","SG9999014914.USD","SG9999004303.SGD","BK4548","LU2471134796.USD","LU2506951792.HKD","LU1935043023.USD","NVDS","LU0557290698.USD","LU0943347566.SGD","LU1069344957.HKD","LU1868837300.USD","SG9999002232.USD","IE00BKPKM429.USD","BK4612","LU1127390331.HKD","LU0786609619.USD","LU2125909759.SGD","NVD3.UK","LU1791710582.SGD","IE0004445015.USD","LU0072462426.USD","LU2271345857.HKD","LU2237438978.USD","LU2023251221.USD","LU2361044949.HKD","LU2746668974.SGD","LU0158827948.USD","LU0708995401.HKD","LU2237957811.SGD","LU2054465674.USD","LU2106854487.HKD","IE00BDRTCR15.USD","LU2089283258.USD","LU1267930730.SGD","LU2272731782.SGD","LU0820561909.HKD","SG9999014880.SGD","LU2247934214.USD","LU2264538146.SGD","LU1623119135.USD","SGXZ81514606.USD","LU0823414551.USD","MCHP","LU1992135472.HKD","LU1064131342.USD","LU0096364046.USD","SG9999015341.SGD","LU0203201768.USD","LU0348723411.USD","IE00B1BXHZ80.USD","LU2111349929.HKD","LU2326559502.SGD","LU2552382215.SGD","LU2381873111.SGD","LU1551013342.USD","LU1551013425.SGD","LU2552382132.HKD","LU0211328371.USD","LU2168564149.EUR","IE0009356076.USD","LU2168564222.USD","LU0265550946.USD","LU0198837287.USD","LU0265550359.USD","LU0979878070.USD","LU0950375773.USD","SG9999015945.SGD","LU0342679015.USD","LU0466842654.USD","LU1923622614.USD","GB00BDT5M118.USD","LU2458330243.SGD","LU1815336760.USD","IE00B4JS1V06.HKD","LU2413666699.HKD","LU0211327993.USD","IE00BMPRXR70.SGD","LU0345768740.USD","LU1037948541.HKD","LU0210536198.USD","LU2065169927.USD","BK4533","IE0004091025.USD","BK4585","LU1791710400.SGD","LU2430703095.HKD","LU0942090050.USD","SGXZ51526630.SGD","IE00BJJMRX11.SGD","LU1633808545.USD","LU1642822529.SGD","LU2896262040.SGD","BK4592","LU1839511570.USD","LU1721428933.USD","LU2236285917.USD","LU2237957902.USD","HK0000320264.USD","LU2750360641.GBP","LU1988902786.USD","LU1868836757.USD","IE00BQXX3D17.EUR","LU0056508442.USD","LU0154236417.USD","LU0823421416.USD","LU2506951875.HKD","LU2430703178.SGD","LU2413666426.HKD","LU2602419157.SGD","LU0353189763.USD","LU0316494557.USD","LU1951198990.SGD","BK4605","LU1718418525.SGD","LU0053666078.USD","LU2756315318.SGD","LU2097344431.USD","LU1989772923.USD","LU1923623000.USD","NVDX","LU2168564495.EUR","LU1145028129.USD","LU2125154778.USD","LU1244550494.USD","LU0672654240.SGD","LU0511384066.AUD","IE0005OL40V9.USD","LU0267386448.USD","LU2506952170.USD","LU1983260115.SGD","LU1868836591.USD","LU0048584097.USD","LU2083900584.USD","LU0094547139.USD","LU2294711713.HKD","LU2357125470.USD","LU0347712357.USD","LU1037948897.HKD","LU0175139822.USD","LU2471134879.HKD","LU1035775433.USD","LU0081259029.USD","LU1066051498.USD","LU0323591593.USD","LU2860962120.EUR","BK4201"],"gpt_icon":1},{"id":"2601365310","title":"Gilead : RBC Cuts Target Price to $100 From $105","url":"https://stock-news.laohu8.com/highlight/detail?id=2601365310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601365310?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:24","pubTimestamp":1767871466,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","BK4583","LU2468319806.SGD","LU1674673428.USD","LU0320765992.SGD","SG9999015952.SGD","LU0109394709.USD","IE00BSNM7G36.USD","LU0889565916.HKD","BK4578","BK4588","BK4568","LU0234570918.USD","SG9999015945.SGD","SG9999015978.USD","IE0002270589.USD","LU1585245621.USD","BK4139","LU0289739699.SGD","LU0114720955.EUR","SG9999015986.USD","LU1430594728.SGD","LU2087621335.USD","LU1674673691.USD","LU0058720904.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","LU1066051498.USD","LU0882574055.USD","IE00B7SZLL34.SGD","LU2324357040.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4585","LU1778281490.HKD","LU1839511570.USD","BK4532","BK4550","GILD","IE00BKVL7J92.USD","BK4566","IE00B19Z3581.USD","LU2089984988.USD","LU0823416689.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}